Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Orion Corporation, Orionintie 1, FIN-02200, Espoo, Finland
Eldepryl 5 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablets for oral administration. |
Selegiline hydrochloride 5 mg.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Selegiline |
Selegiline is a selective MAO-B-inhibitor which prevents dopamine breakdown in the brain. It also inhibits the reuptake of dopamine at the presynaptic dopamine receptor. These effects potentiate dopaminergic function in the brain and help to even out and prolong the effect of exogenous and endogenous dopamine. Thus, selegiline potentiates and prolongs the effect of levodopa in the treatment of parkinsonism. |
| List of Excipients |
|---|
|
Mannitol |
a) White HDPE bottle with LDPE snap cap: 100 tablets.
b) AI/AI blister packs: 30, 50, 60 and 100 tablets.
c) White HDPE bottle with HDPE screw cap: 100 tablets.
Orion Corporation, Orionintie 1, FIN-02200, Espoo, Finland
PL 27925/0004
Date of first authorization: 01 July 1993
Date of latest renewal: July 2007
| Drug | Countries | |
|---|---|---|
| ELDEPRYL | Australia, Finland, Ireland, Malta, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
